In the context of CAR-T cell therapies for cancer, there is a need to further explore the optimal treatment strategy including treatment dosage, frequency, and treatment route of proteasome inhibitors when combined with the BCMA targeted CAR-T cells 93, 94, 146. The gene discussed is TNFRSF17; the disease is cancer.